KLC
AKYA

Kent Lake Capital’s Akoya BioSciences AKYA Stock Holding History

Kent Lake Capital’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-116,835
Closed -$570K – 44
2023
Q4 		$570K Sell
116,835
-629,686
-84% -$2.62M 0.22% 45
2023
Q3 		$3.47M Buy
+746,521
New +$4.29M 1.33% 28

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kent Lake Capital's AKYA Position: Q1 2024 in Review

Kent Lake Capital sold out of Akoya BioSciences (AKYA) in Q1 2024, closing a stake of 116,835 shares — an estimated $570K sold.

Kent Lake Capital first reported a position in AKYA in Q3 2023 and held it in 2 quarters. The position peaked at $3.47M in Q3 2023. 68 funds tracked by Wall St. Rank hold AKYA as of Q1 2024.

  • Kent Lake Capital reported no remaining Akoya BioSciences position as of Q1 2024 after selling out during the quarter.
  • Kent Lake Capital sold 116,835 Akoya BioSciences shares in Q1 2024, an estimated $570K.
  • Kent Lake Capital first reported a position in Akoya BioSciences in Q3 2023 and held it in 2 quarters.
  • Kent Lake Capital's Akoya BioSciences position peaked at $3.47M in Q3 2023.
  • 68 funds tracked by Wall St. Rank held Akoya BioSciences as of Q1 2024.

Based on Kent Lake Capital's 13F filing for Q1 2024, filed 15 May 2024.